AMIKACIN IN THE TREATMENT OF PULMONARY TUBERCULOSIS
AMIKACIN IN THE TREATMENT OF PULMONARY TUBERCULOSIS
复制标题
DOI：
10.1016/0041-3879(83)90035-1
复制
发表时间：
1983-01-01
期刊：
影响因子：
--
通讯作者：
GIRLING, DJ
中科院分区：
文献类型：
--
作者：
ALLEN, BW;MITCHISON, DA;GIRLING, DJ
对11例曾接受卡那霉素和/或卷曲霉素治疗的肺结核患者的菌株进行敏感性试验，显示阿米卡星和卷曲霉素之间存在不完全交叉耐药性，但阿米卡星和卡那霉素之间存在完全交叉耐药性。经痰涂片和培养评估，4 名多重耐药菌株患者接受阿米卡星治疗后无反应；出现了对阿米卡星、卡那霉素和卷曲霉素的耐药性。在治疗结核病时，阿米卡星不能替代卡那霉素；它没有治疗优势并且更昂贵。
Sensitivity tests on strains from 11 patients with pulmonary tuberculosis, previously treated with kanamycin and/or capreomycin, showed incomplete cross-resistance between amikacin and capreomycin but complete cross-resistance between amikacin and kanamycin. Treatment with amikacin of 4 patients with multiply resistant strains resulted in no response as assessed by sputum smears and cultures; resistance emerged to amikacin, kanamycin and capreomycin. Amikacin cannot be given as an alternative to kanamycin in the treatment of tuberculosis; it has no therapeutic advantages and is more expensive.